Acute and recurrent DVT, PE, and post-thrombotic syndrome impose a high economic burden, highlighting the potential economic and clinical benefits of early detection and appropriate treatment.
High VTE costs support prevention research; leaves open whether interventions reduce burden in prospective trials.
These data suggest that the initial acute DVT or PE event is associated with high total health care costs and that these costs are further increased by subsequent events such as recurrent DVT or PE and PTS. Early detection and appropriate treatment of this high-risk population have the potential for both clinical and economic benefits.
No takes yet. Share an insight, caveat, or question.
MacDougall et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: